Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03660228 · ClinicalTrials.gov registry record · NA
Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 62
- Enrollment target
NCT03660228 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 62 participants.
The verdict
NCT03660228, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 62 participants
- Enrollment target
Study Summary
This research study is evaluating how to best tailor blood transfusion decisions to match the quality of life changes experienced by individual patients with MDS.
Interventions
- OTHER Peri-Transfusion QOL Assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2018-10-17 |
| Est. Completion | 2021-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03660228
The ClinicalTrials.gov registry entry for NCT03660228 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peri-Transfusion QOL Assessment is the first listed.
NCT03660228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03660228 about?
NCT03660228 is a clinical study titled "Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS". This research study is evaluating how to best tailor blood transfusion decisions to match the quality of life changes experienced by individual patients with MDS.
What is the current status of trial NCT03660228?
This trial is currently completed. It is a NA study. The enrollment target is 62 participants. The study started on 2018-10-17. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT03660228?
The interventions under investigation include: Peri-Transfusion QOL Assessment (OTHER).
Who is sponsoring clinical trial NCT03660228?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.